FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2579884408> ?p ?o ?g. }

• W2579884408 abstract "Abstract INTRODUCTION: Previous studies have demonstrated the clinical activity of the mTOR inhibitor RAD001 in low- grade lymphomas. Our preclinical studies demonstrated activity of mTOR inhibitors in Waldenstrom Macroglobulinemia (WM) cell lines and patient samples. This phase II study aimed to determine safety and activity of the oral mTOR inhibitor RAD001 (Novartis Pharmaceutical, MA) in patients with relapsed or refractory WM. METHODS: Patients who had at least one previous therapy for WM, and who had symptomatic relapsed or refractory disease were eligible. NCI CTCAE v3.0 was used for toxicity assessment. All patients received daily RAD001 at 10 mg. A cycle was considered 28 days. Patients were allowed to stay on therapy until progression of disease or excessive toxicity. This study was conducted in a collaborative effort between Dana Farber Cancer Institute (DFCI) and Mayo Clinic College of Medicine. Here, we report the data on the patients accrued at DFCI. RESULTS: 19 pts (15 men and 4 women) have been treated to date. All patients had symptomatic disease and required therapy. The median number of lines of prior treatment was 3 (range 1 – 5) including included rituximab, nucleoside analogues (fludarabine or 2-CDA), combination chemotherapy (e.g. CHOP, CVP), chloramucil, and bortezomib. The median IgM at baseline was 3330 mg/dL (range 1010– 7410). The median follow on RAD001 was 8 months (range 3 – 22 months). Eighteen pts are currently evaluable for response. Best responses to RAD001 after 2 cycles using IgM monoclonal protein were as follows: partial remission in 8 (44%), minimal response in 5 (28%). Progressive disease occurred in 4 (22%) and stable disease occurred in 1 (6%). The overall response rate (PR+MR) was 72%. The median duration of response has not been reached (3–22+ months). Patients tolerated therapy well without significant toxicities. Grade 3 and 4 toxicities included grade 4 thrombocytopenia in 1 patient, grade 3 pneumonia in 1 patient, grade 3 hyperglycemia in 1 patient and grade 3 mucositis in 1 patient. Other adverse events of grade 2 or lower included nail cracking, mucositis, diarrhea, and fatigue. Attributable toxicities otherwise proved manageable with appropriate supportive care, and RAD001 was generally well tolerated. One patient enrolled on the study withdrew consent and changed to hospice care within 3 weeks of therapy, and passed away due to disease progression. CONCLUSIONS: The use of the oral RAD001 single agent RAD001 in patients with relapsed or refractory WM was welltolerated and demonstrated significant activity achieving an overall response rate in 72% of patients. Future studies of combination of this agent with rituximab and bortezomib are currently being planned." @default.
• W2579884408 created "2017-01-26" @default.
• W2579884408 creator A5004152557 @default.
• W2579884408 creator A5023152679 @default.
• W2579884408 creator A5032464400 @default.
• W2579884408 creator A5033781840 @default.
• W2579884408 creator A5035416071 @default.
• W2579884408 creator A5042578998 @default.
• W2579884408 creator A5043526996 @default.
• W2579884408 creator A5056481400 @default.
• W2579884408 creator A5061148041 @default.
• W2579884408 creator A5070360113 @default.
• W2579884408 creator A5081041356 @default.
• W2579884408 creator A5081299017 @default.
• W2579884408 creator A5082924494 @default.
• W2579884408 creator A5083104525 @default.
• W2579884408 creator A5088343926 @default.
• W2579884408 date "2008-11-16" @default.
• W2579884408 modified "2023-10-07" @default.
• W2579884408 title "Phase II Trial of the mTOR Inhibitor RAD001 in Relapsed and/or Refractory Waldenstrom Macroglobulinemia: The Dana Farber Cancer Institute Experience." @default.
• W2579884408 doi "https://doi.org/10.1182/blood.v112.11.1011.1011" @default.
• W2579884408 hasPublicationYear "2008" @default.
• W2579884408 type Work @default.
• W2579884408 sameAs 2579884408 @default.
• W2579884408 citedByCount "2" @default.
• W2579884408 countsByYear W25798844082014 @default.
• W2579884408 crossrefType "journal-article" @default.
• W2579884408 hasAuthorship W2579884408A5004152557 @default.
• W2579884408 hasAuthorship W2579884408A5023152679 @default.
• W2579884408 hasAuthorship W2579884408A5032464400 @default.
• W2579884408 hasAuthorship W2579884408A5033781840 @default.
• W2579884408 hasAuthorship W2579884408A5035416071 @default.
• W2579884408 hasAuthorship W2579884408A5042578998 @default.
• W2579884408 hasAuthorship W2579884408A5043526996 @default.
• W2579884408 hasAuthorship W2579884408A5056481400 @default.
• W2579884408 hasAuthorship W2579884408A5061148041 @default.
• W2579884408 hasAuthorship W2579884408A5070360113 @default.
• W2579884408 hasAuthorship W2579884408A5081041356 @default.
• W2579884408 hasAuthorship W2579884408A5081299017 @default.
• W2579884408 hasAuthorship W2579884408A5082924494 @default.
• W2579884408 hasAuthorship W2579884408A5083104525 @default.
• W2579884408 hasAuthorship W2579884408A5088343926 @default.
• W2579884408 hasConcept C126322002 @default.
• W2579884408 hasConcept C141071460 @default.
• W2579884408 hasConcept C143998085 @default.
• W2579884408 hasConcept C2776364478 @default.
• W2579884408 hasConcept C2776391228 @default.
• W2579884408 hasConcept C2776694085 @default.
• W2579884408 hasConcept C2776755627 @default.
• W2579884408 hasConcept C2777478702 @default.
• W2579884408 hasConcept C2778822529 @default.
• W2579884408 hasConcept C2779263901 @default.
• W2579884408 hasConcept C2779338263 @default.
• W2579884408 hasConcept C2779699572 @default.
• W2579884408 hasConcept C2780653079 @default.
• W2579884408 hasConcept C2781038049 @default.
• W2579884408 hasConcept C31760486 @default.
• W2579884408 hasConcept C71924100 @default.
• W2579884408 hasConcept C90924648 @default.
• W2579884408 hasConceptScore W2579884408C126322002 @default.
• W2579884408 hasConceptScore W2579884408C141071460 @default.
• W2579884408 hasConceptScore W2579884408C143998085 @default.
• W2579884408 hasConceptScore W2579884408C2776364478 @default.
• W2579884408 hasConceptScore W2579884408C2776391228 @default.
• W2579884408 hasConceptScore W2579884408C2776694085 @default.
• W2579884408 hasConceptScore W2579884408C2776755627 @default.
• W2579884408 hasConceptScore W2579884408C2777478702 @default.
• W2579884408 hasConceptScore W2579884408C2778822529 @default.
• W2579884408 hasConceptScore W2579884408C2779263901 @default.
• W2579884408 hasConceptScore W2579884408C2779338263 @default.
• W2579884408 hasConceptScore W2579884408C2779699572 @default.
• W2579884408 hasConceptScore W2579884408C2780653079 @default.
• W2579884408 hasConceptScore W2579884408C2781038049 @default.
• W2579884408 hasConceptScore W2579884408C31760486 @default.
• W2579884408 hasConceptScore W2579884408C71924100 @default.
• W2579884408 hasConceptScore W2579884408C90924648 @default.
• W2579884408 hasLocation W25798844081 @default.
• W2579884408 hasOpenAccess W2579884408 @default.
• W2579884408 hasPrimaryLocation W25798844081 @default.
• W2579884408 hasRelatedWork W12229326 @default.
• W2579884408 hasRelatedWork W2098002594 @default.
• W2579884408 hasRelatedWork W2161574806 @default.
• W2579884408 hasRelatedWork W2225835123 @default.
• W2579884408 hasRelatedWork W2474589366 @default.
• W2579884408 hasRelatedWork W2475736659 @default.
• W2579884408 hasRelatedWork W2530337073 @default.
• W2579884408 hasRelatedWork W2533720156 @default.
• W2579884408 hasRelatedWork W2550544585 @default.
• W2579884408 hasRelatedWork W2554569362 @default.
• W2579884408 hasRelatedWork W2558768338 @default.
• W2579884408 hasRelatedWork W2558848711 @default.
• W2579884408 hasRelatedWork W2559274062 @default.
• W2579884408 hasRelatedWork W2562167373 @default.
• W2579884408 hasRelatedWork W2573079206 @default.
• W2579884408 hasRelatedWork W2590111115 @default.
• W2579884408 hasRelatedWork W2979401570 @default.
• W2579884408 hasRelatedWork W2980472107 @default.
• W2579884408 hasRelatedWork W433802874 @default.
• W2579884408 hasRelatedWork W767219806 @default.
• W2579884408 isParatext "false" @default.

• next